Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia.
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.